greeksoup/ stock research

Pfizer (PFE) Q3 FY2023 earnings: revenue $13.5 billion, down 40.4% on the year

Pfizer Inc. (PFE) reported revenue of $13.5 billion for Q3 FY2023, the quarter ended 1 October 2023, down 40.4% on the same quarter a year earlier. Net income was -$2.4 billion, and diluted earnings per share $-0.42. The figures are the company's own, from the 10-Q it filed with the SEC on 8 November 2023.

Revenue
$13.5 billion
-40.4% on the year · +3.7% on the quarter
Q4 FY2021Q3 FY2023
Operating margin
n/a
Q4 FY2021Q3 FY2023
Net income
-$2.4 billion
Q4 FY2021Q3 FY2023
Diluted EPS
-$0.42
Q4 FY2021Q3 FY2023

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ3 FY2023Q2 FY2023Q3 FY2022On the quarterOn the yearLast 8 quarters
Revenue13,49113,00722,638+3.7%-40.4%
Cost of revenue9,2693,2376,063+186.3%+52.9%
Gross profit4,2229,77016,575-56.8%-74.5%
Gross margin31.3%75.1%73.2%
Research and development2,7112,6482,696+2.4%+0.6%
Selling, general and administrative3,2813,4973,391-6.2%-3.2%
Interest expense695508311+36.8%+123.5%
Pre-tax income-3,3522,2699,001
Income tax-964-71.0356
Effective tax raten/a-3.1%4.0%
Net income-2,3822,3278,608
Net margin-17.7%17.9%38.0%
Diluted EPS-$0.42$0.41$1.51
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ3 FY2023Q2 FY2023Q3 FY2022On the quarterOn the yearLast 8 quarters
Operating cash flow3,456-1,2085,974-42.1%
Capital expenditure810914841-11.4%-3.7%
Free cash flow2,646-2,1225,133-48.5%
Free cash flow margin19.6%-16.3%22.7%
Cash from investing888-25,485-627
Cash from financing-3,77927,174-5,761
Depreciation and amortisation1,5601,5731,183-0.8%+31.9%
Share-based compensation151148135+2.0%+11.9%
Buybacks0.00.00.0
Dividends paid2,3142,3152,245-0.0%+3.1%
Dividend per share$0.00$0.82$0.40
Diluted shares, weighted5,646m5,713m5,718m-1.2%-1.3%
Shares outstanding at period end5,646m5,646m5,646m+0.0%0.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2023Q2 FY2023Q3 FY2022On the quarterOn the yearLast 8 quarters
Shareholders' equity96,93499,01992,631-2.1%+4.6%
Non-controlling interest270274259-1.5%+4.2%
Debt63,30865,34136,669-3.1%+72.6%
Other liabilities54,50955,53465,791-1.8%-17.1%
Total liabilities and equity215,021220,168195,350-2.3%+10.1%
Fixed assets17,86217,48815,441+2.1%+15.7%
Goodwill51,52751,57249,441-0.1%+4.2%
Intangible assets40,22441,40628,151-2.9%+42.9%
Investments40,48639,15734,064+3.4%+18.9%
Cash and equivalents3,1482,6321,298+19.6%+142.5%
Receivables11,08610,23116,076+8.4%-31.0%
Inventory10,20410,3109,513-1.0%+7.3%
Other assets40,48447,37241,366-14.5%-2.1%
Total assets215,021220,168195,350-2.3%+10.1%

Questions

What was Pfizer's revenue in Q3 FY2023?

Pfizer (PFE) reported revenue of $13.5 billion for Q3 FY2023, the quarter ended 1 October 2023, down 40.4% on the same quarter a year earlier.

How much did Pfizer earn in Q3 FY2023?

Net loss for Q3 FY2023 was $2.4 billion, and the diluted loss per share $0.42.

When did Pfizer report Q3 FY2023 results?

Pfizer filed its 10-Q for the quarter ended 1 October 2023 with the SEC on 8 November 2023.

Quarterly results, the last 20 quarters

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue23,63525,66127,74222,63824,28918,48613,00713,49114,24814,87913,28317,70217,76313,71514,65316,65417,55714,45115,03416,583
Cost of revenue9,7369,9848,6486,0639,6494,8863,2379,2697,5623,3793,3005,2635,9092,8453,7784,1725,2723,5484,0924,028
Gross profit13,89915,67719,09416,57514,64013,6009,7704,2226,68611,5009,98312,43911,85410,87010,87512,48212,28510,90310,94212,555
Gross margin59%61%69%73%60%74%75%31%47%77%75%70%67%79%74%75%70%75%73%76%
R&D5,9092,3012,8152,6963,6162,5052,6482,7112,8152,4932,6962,5983,0352,2032,4822,5463,2062,4902,8093,016
SG&A4,0992,5933,0483,3914,6453,4183,4973,2814,5753,4953,7173,2444,2743,0313,4153,1864,1622,9613,4113,279
Interest expense314322293311312318508695688790778783740654654652711668667662
Pre-tax income3,8439,05011,4479,0015,2316,2702,269-3,352-4,1293,421-1034,715-10.02,7853,0443,334-1,6433,170-6533,385
Tax rate6%13%14%4%4%11%-3%n/an/a9%n/a5%n/a-7%5%-6%n/a15%n/a4%
Net income3,3937,8649,9068,6084,9945,5432,327-2,382-3,3693,11541.04,4654102,9672,9103,541-1,6472,687-2483,242
Net margin14%31%36%38%21%30%18%-18%-24%21%0%25%2%22%20%21%-9%19%-2%20%
Diluted EPS$0.59$1.37$1.73$1.51$0.87$0.97$0.41-$0.42-$0.60$0.55$0.01$0.78$0.07$0.52$0.51$0.62-$0.29$0.47-$0.04$0.56
Operating cash flow5,9146,5418,1705,9748,5821,212-1,2083,4565,2401,090-1,7816,7146,7212,335-5824,6035,3482,6158355,375
Capital expenditure9936437518411,0011,1399148101,044704637651917564618602845436533573
Free cash flow4,9215,8987,4195,1337,58173.0-2,1222,6464,196386-2,4186,0635,8041,771-1,2004,0014,5032,1793024,802
Buybacks0.02,0000.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid2,1892,2492,2442,2452,2452,3032,3152,3142,3152,3722,3802,3802,3802,4372,4452,4442,4452,4452,4512,451
Shares outstanding5,619m5,645m5,646m5,646m5,619m5,645m5,646m5,646m5,647m5,667m5,667m5,667m5,667m5,685m5,686m5,686m5,686m5,699m5,700m5,700m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 1 October 2023, filed 8 November 2023: the filing.